|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
Improving pathologic nodal staging of resected lung cancer
|
2R01CA172253-06
|
$499,347
|
|
OSAROGIAGBON, RAYMOND
|
BAPTIST MEMORIAL HOSPITAL - TIPTON
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-02S1
|
$7,156
|
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and Targeting Onocgenic MYC Enhancer Control in Pediatric Tumors
|
3R01CA215452-02S2
|
$45,800
|
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
5R01CA181808-05
|
$336,565
|
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma
|
5R03CA215940-02
|
$75,288
|
|
YUSTEIN, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
5R01CA202797-03
|
$349,694
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
5U54CA209978-03
|
$2,154,776
|
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia
|
1R44CA224848-01A1
|
$348,768
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.
|
1R44CA228694-01
|
$300,000
|
|
SILBERSTEIN, DAVID
|
BIOMIMETIX JV, LLC
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
1R01CA211328-01
|
$404,888
|
$404,888
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Developing a translational pipeline for NF1-mutant malignancies
|
5U01CA202943-03
|
$235,046
|
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A novel small molecule FL7N-1 for treating pediatric cancer retinoblastoma
|
1R43CA221389-01A1
|
$224,919
|
|
LING, XIANG
|
CANGET BIOTEKPHARMA, LLC
|
|
Determining the Epigenetic Mechanisms Driving Tissue Factor (F3) Upregulation and its Role in Metastatic Osteosarcoma
|
5F31CA213965-02
|
$44,524
|
|
BAYLES, IAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Treatment of glioblastoma using targeted nanoparticles
|
3U01CA198892-04S1
|
$66,200
|
|
COVARRUBIAS, GIL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Defining novel drivers and predictive signatures of metastasis in osteosarcoma th
|
5F30CA186633-05
|
$49,524
|
|
MORROW, JAMES
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cancer Initiating Cells and Treatment Resistance
|
7R01CA193590-04
|
$368,551
|
|
PAN, QUINTIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
The Development of Novel Mechanistically-based APE/Ref-1 Redox Inhibitors
|
5K08CA179084-05
|
$112,331
|
|
YANG, SUN
|
CHAPMAN UNIVERSITY
|
|
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion
|
5R01CA189299-04
|
$338,550
|
|
KELLER, CHARLES
|
CHILDREN'S CANCER THERAPY DEVELOP/INST
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
$83,611
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-04
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-04
|
$22,547,116
|
$1,352,827
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers
|
1U54CA232568-01
|
$12,197,183
|
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exosomes in tumor cell-mesenchymal stromal cell interaction
|
5R01CA207983-02
|
$449,691
|
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Training Physician Scientists in Pediatric Oncology
|
5T32CA009659-23
|
$214,456
|
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
|
5P01CA217959-02
|
$2,171,238
|
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
An organotypic model recapitulating colon cancer microenvironment and metastasis
|
5U01CA214300-02
|
$673,627
|
|
HUANG, EMINA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer
|
1R44CA224472-01A1
|
$298,791
|
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
|
Pre-IND development of CBT-15 monoclonal antibody therapy against renal cell cancer
|
1R44CA228895-01A1
|
$298,835
|
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
|
5U01CA217858-02
|
$1,314,469
|
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Evaluating Notch Signaling as a Therapeutic Target in Ovarian Cancer
|
5F31CA192891-05
|
$49,524
|
|
PRICE, JESSICA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of Fusobacterium in colorectal cancer treatment, tumor ecology and chemotherapeutic efficacy
|
1K99CA229984-01
|
$128,963
|
|
BULLMAN, SUSAN
|
DANA-FARBER CANCER INST
|
|
The Cellular Geography of Therapeutic Resistance in Cancer
|
1U2CCA233195-01
|
$2,521,976
|
|
HAINING, WILLIAM
|
DANA-FARBER CANCER INST
|
|
Elucidating and overcoming endocrine resistance driven by ESR1 mutations
|
5K08CA191058-04
|
$177,120
|
|
JESELSOHN, RINATH
|
DANA-FARBER CANCER INST
|
|
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
|
1U01CA233084-01
|
$829,650
|
|
KUFE, DONALD
|
DANA-FARBER CANCER INST
|
|
Primers: Combining Radiotherapy and Immunotherapy using next genertaion radiotherapy biomaterials
|
5R21CA205094-02
|
$191,669
|
|
NGWA, WILFRED
|
DANA-FARBER CANCER INST
|
|
Targeting intratumor heterogeneity in breast cancer
|
5R35CA197623-04
|
$1,157,073
|
|
POLYAK, KORNELIA
|
DANA-FARBER CANCER INST
|
|
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
|
3R01CA204915-02S1
|
$228,600
|
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INST
|
|
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
|
3R01CA204915-02S2
|
$40,302
|
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INST
|
|
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
|
1U01CA233100-01
|
$841,459
|
|
VAN ALLEN, ELIEZER
|
DANA-FARBER CANCER INST
|
|
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
|
5P01CA206978-03
|
$1,755,838
|
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
|
5R35CA210057-03
|
$1,007,233
|
|
ZHAO, JEAN
|
DANA-FARBER CANCER INST
|
|
Exploiting the epithelial-to-mesenchymal transition for the differentiation of cancer stem cells
|
4R00CA201574-03
|
$249,000
|
|
PATTABIRAMAN, DIWAKAR
|
DARTMOUTH COLLEGE
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-05
|
$435,560
|
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
Total relevant funding to Wilm's Tumor for this search: $4,995,401
|